Back to results
US 2026/0000697 A1Published application
Combination formulation of cedazuridine
AssigneeOtsuka Pharmaceutical Co., Ltd.
InventorsNipun Davar, Jim Kou, Rachna Jain
Life of this patent
Estimating the term…
Abstract
The present disclosure relates generally to pharmaceutical dosage forms comprising azacitidine and cedazuridine.
Claims39
A pharmaceutical dosage form comprising cedazuridine, or a pharmaceutically acceptable salt thereof, and azacitidine, or a pharmaceutically acceptable salt thereof, wherein at least a portion of the azacitidine is formulated for modified release.
A pharmaceutical dosage form comprising cedazuridine, or a pharmaceutically acceptable salt thereof, and azacitidine, or a pharmaceutically acceptable salt thereof, wherein:
- the cedazuridine is formulated for immediate release;
- and
- the azacitidine is formulated as modified release minitablets comprising an enteric coat.
A capsule comprising:
- one or more azacitidine minitablets formulated for modified release, comprising azacitidine or a pharmaceutically acceptable salt thereof, pharmaceutically acceptable excipients, and an enteric coat;
- and
- immediate release cedazuridine in a form of uncoated powder or blends, comprising cedazuridine or a pharmaceutically acceptable salt thereof and pharmaceutically acceptable excipients.
39-50. (canceled)
Dependencies are inferred from the claim text.